A former critic of FDA and Pharma will now oversee the regulation of costly and complicated biologics like vaccines, gene therapies, and blood supply.

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

DUBLIN, May 13, 2025 - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the appointment of Susan Rodriguez ...

Robert F. Kennedy Jr. goes to Capitol Hill to promote and defend his massive overhaul of HHS, and President Trump's plans to ...

Now is the time for the biotechnology sector to ask for big changes to the FDA, NIH, reimbursement, intellectual property and ...

Regulatory environment tightening with FDA leadership change, adding uncertainty to Sarepta's near-term outlook and potential delays in approvals. However, the stock has underperformed since then ...

These 26 stocks are working on everything from early diagnostics to drug discovery ... relative to broader benchmarks. The recent leadership changes, particularly Sam Altman's departure and ...

Q: How are recent FDA leadership changes affecting MaxCyte and its customers? A: Maher Masood, President and CEO, stated that it's too early to determine the impact of FDA leadership changes. However, ...

Supporting Doug Meyers’ comments on Holocaust comparison This letter supports Mr. Doug Meyers’ letter printed Friday, May 2, ...

Q: Can you provide insights on the demand from cell and gene therapy customers following the recent FDA leadership change and any improvements in the biotech funding landscape? A: Steven Gunstream ...

Business leaders report that revenue from restaurants, alcohol sales, and local accommodations has plummeted, despite Burlington entering its peak tourist season ...

Regulatory uncertainties under Dr. Vinay Prasad's FDA leadership could delay approvals ... and there have been some notable changes in the FDA that impact its regulatory prospects.